The positive signal found in this pilot warrants the conduction oflarger trials using ivermectin for the early treatment of COVID-19.Such trials should include patients with risk factors for severe diseaseas well as patients with pneumonia. The potential for a mechanism ofaction different to direct antiviral effect also opens the door for pre-exposure prophylaxis in high-risk group